China’s competitive position in translational cancer research

At this year’s ASCO meeting, Chinese companies nearly matched North American biopharmas in number of published abstracts describing first-in-human trials, underscoring how far the region has come in its shift toward innovative medicine development, as well as its growing role as a source of new technologies and programs. 

BioCentury’s analysis of first-in-human trials presented at this year’s American Society of Clinical Oncology (ASCO) conference focused on those with no disclosed readouts prior to the meeting. Chinese biopharmas ranked second only to U.S. companies in the number of abstracts that met that description...